CASE IMAGE

ExcLAMation marks in a pelvic lymph node

Yuki Muroyama¹ | Chihiro Inoue² | Fumiyoshi Fujishima¹ | Shogo Shigeta³ | Junko Hasegawa-Minato³ | Muneaki Shimada³ | Takashi Suzuki^{1,2}

Correspondence

Yuki Muroyama, Department of Pathology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. Email: yuki.muroyama.a3@tohoku. ac.jp

Key Clinical Message

Extrapulmonary lymphangioleiomyomatosis (LAM) can present as incidental nodal LAM in gynecological surgery specimens, that warrants systemic investigation and follow-up of concurrent and subsequent development of pulmonary and extrapulmonary LAM.

KEYWORDS

gynecology, lymph nodes, Lymphangioleiomyomatosis, pathology

1 | CASE PRESENTATION

65-year-old female presented with vaginal bleeding and lower abdominal pain. She underwent total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy, and the postoperative diagnosis was determined as uterine endometrioid carcinoma, Grade 2, pT2, pN0, cM0, pStage II, based on the TNM Classification of Malignant Tumors, 8th edition. Although preoperative computed tomography (CT) scan did not reveal clear enlargement of lymph nodes, pathological examination of a dissected common iliac lymph node revealed multiple lesions, maximally 5 mm in size, that consist of bundles of spindle cells and nests of epithelioid cells, with grainy, eosinophilic cytoplasm, ovoid nuclei with small nucleoli (Figure 1A,C). The cells did not reveal atypia, mitotic activity nor necrosis, and morphologically distinct from primary endometrioid carcinoma. Immunohistochemistry showed characteristic D2-40 (podoplanin) positive lymphatic endothelium lining the bundles of spindle cells and nests of epithelioid cells (Figure 1B,D). $\alpha\text{-smooth}$ muscle actin ($\alpha\text{-SMA}$), estrogen receptor (ER), and cytoplasmic $\beta\text{-catenin}$ were diffusely positive, but cytokeratin (AE1/AE3) and CD34 were negative. Taken together, diagnosis of nodal lymphangioleiomyomatosis (LAM) was made. Melanocytic markers such as HMB45 and Melan-A, which are often positive in LAM, were positive only in a few cells in this case. Postoperative follow-up systemic investigation did not reveal other suspected LAM lesions including lung.

2 DISCUSSION

LAM is a rare systemic disease that affect mostly women of childbearing age, characterized by proliferation of smooth muscle-like cells (LAM cells). Although LAM


This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.


© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.


¹Department of Pathology, Tohoku University Hospital, Sendai, Japan

²Department of Anatomic Pathology, Graduate School of Medicine, Tohoku University, Sendai, Japan

³Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan










FIGURE 1 Nodal lymphangioleiomyomatosis (LAM) in a common iliac lymph node. (A, C) Hematoxylin and eosin (HE) staining showed the bundles of spindle cells and nests of epithelioid cells in a common iliac lymph node. (B, D) D2-40 (podoplanin) expression in the lymphatic endothelium lining the spindle-cell bundles and epithelioid-cell nests. (A, B) Loupe images capturing the whole lymph node. Representative LAM lesions are shown with black arrowheads. Scale bar: 5 mm. (C, D) Representative magnified views. Scale bar: 500 μm.

often manifests as progressive formation of pulmonary parenchymal cysts, extrapulmonary LAM can involve other organs, including mediastinum, retroperitoneum, uterus, intraperitoneal and/or pelvic lymph nodes, with or without pulmonary involvement.¹

Incidental nodal LAM can be found in 0.46% of the lymph nodes of gynecologic surgical specimens.² Cases of incidental nodal LAM with subsequent development of pulmonary LAM have been reported,^{2,3} including the development of pulmonary LAM 7 years post initial identification of nodal LAM,² warranting precautious attention and long-term follow-up.

When nodal LAM was identified, it would be prudent to systemically investigate and follow-up concurrent and subsequent development of pulmonary and extrapulmonary LAM.

Acronyms: CT: computed tomography, LAM: lymphangioleiomyomatosis, ER: Estrogen Receptor, CD: Cluster of Differentiation, α -SMA: smooth muscle actin, HMB: Human Melanoma Black, HE: Hematoxylin and eosin.

AUTHOR CONTRIBUTIONS

Yuki Muroyama: Conceptualization; formal analysis; investigation; project administration; validation; visualization; writing – original draft; writing – review and editing. Chihiro Inoue: Formal analysis; investigation; validation; writing – review and editing. Fumiyoshi Fujishima: Formal analysis; investigation; project administration; resources; supervision; validation; writing – review and editing. Shogo Shigeta: Investigation; project administration; writing – review and editing. Junko Hasegawa-Minato: Investigation; writing – review and editing. Muneaki Shimada: Supervision; writing – review and editing. Takashi Suzuki: Investigation; project administration; resources; supervision; validation; writing – review and editing.

ACKNOWLEDGMENTS

We thank all the staffs of Department of Pathology, Department of Gynecology, and Institutional Review Board of Tohoku University Hospital, and all the staffs of Department of Anatomic Pathology and Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, for their support.

FUNDING INFORMATION

None.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

Not applicable.

ETHICS STATEMENT

This study was approved by the Tohoku University Hospital Institutional Review Board (number 33853).

CONSENT

Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy.

ORCID

Takashi Suzuki https://orcid.org/0000-0003-0195-815X

REFERENCES

- 1. Matsui K, Tatsuguchi A, Valencia J, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. *Hum Pathol.* 2000;31(10):1242-1248. doi:10.1053/hupa.2000.18500
- Kuno I, Yoshida H, Shimizu H, et al. Incidental lymphangioleiomyomatosis in the lymph nodes of gynecologic surgical specimens. Eur J Obstetrics Gynecol Reproduct Biol. 2018;231:93-97. doi:10.1016/j.ejogrb.2018.10.027
- Remo A, Zanella C, Parcesepe P, et al. Diagnostic management of occult nodal lymphangioleiomyomatosis detected during pelvic cancer staging. Localized finding or systemic disease? Sarcoidosis Vasculitis Diffuse Lung Dis. 2019;36(1):33-38. doi:10.36141/svdld.v36i1.7110

How to cite this article: Muroyama Y, Inoue C, Fujishima F, et al. ExcLAMation marks in a pelvic lymph node. *Clin Case Rep.* 2023;11:e8339. doi:10.1002/ccr3.8339